# Abeona Therapeutics

Canonical page: https://technooptimist.io/companies/abeona-therapeutics
US company that makes Zevaskyn: sheets of a patient's own skin cells, gene-corrected to make collagen VII, grafted onto the chronic wounds of recessive dystrophic epidermolysis bullosa.

## In brief

- Zevaskyn approved by FDA April 2025, the first cell-based gene therapy for RDEB wounds.
- Q2 2026 Zevaskyn revenue $11.4M (+31% QoQ); 12 patient treatments since launch.
- Manufacturing yield is the bottleneck: two treatments so far could not be billed.

## Facts

- Headquarters: US
- Status: public
- Website: https://www.abeonatherapeutics.com
- Frontiers: [Biotech](https://technooptimist.io/biotech.md) (Gene therapy)

## Programs

- [Zevaskyn (pz-cel)](https://technooptimist.io/biotech/zevaskyn.md) (Biotech): Deploy; next: Expanding treatment centres and manufacturing yield (2026). On sale; 12 patients treated by Aug 2026; Q2 2026 revenue $11.4M; manufacturing yield limits growth.

## Latest updates

- **13 Aug 2026**: Abeona: Zevaskyn revenue rises 31% to $11.4M in Q2 2026; 12 patients treated since launch. Abeona reported $11.4M of Zevaskyn revenue in Q2 2026, up from $8.7M in Q1, with five patients treated in the quarter and 12 since launch. ([our story](https://technooptimist.io/stories/abeona-zevaskyn-revenue-rises-31-to-11-4m-in-q2-2026-12-patients-7afd710c.md) · [original source](https://www.1stoncology.com/blog/?p=112851))
- **29 Apr 2025**: FDA approves Zevaskyn, the first cell-based gene therapy for wounds of recessive dystrophic epidermolysis bullosa. The FDA approved Zevaskyn (prademagene zamikeracel) for wounds in adults and children with recessive dystrophic epidermolysis bullosa, a genetic disease where skin tears and blisters at the slightest friction. ([our story](https://technooptimist.io/stories/fda-approves-zevaskyn-the-first-cell-based-gene-therapy-for-wounds-of-5800a692.md) · [original source](https://www.europeanpharmaceuticalreview.com/news/254869/fda-approves-first-of-a-kind-gene-therapy-for-dystrophic-epidermolysis-bullosa))

## People

- Vish Seshadri, Chief Executive Officer

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.